Witnessed versus Unwitnessed Random Urine Tests in the Treatment of Opioid Dependence

Ashok Mallya, Amanda L. Purnell, Dragan M. Svrakic, Ann M. Lovell, Kenneth E. Freedland, Britt M. Gott, Gregory S. Sayuk, Theodore J. Cicero, Peter A. Brawer, Jodie A. Trafton, Jeffrey F. Scherrer, Patrick J. Lustman

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Background and Objectives Clinics licensed to provide pharmacotherapy for opiate dependence disorder are required to perform random urine drug screen (RUDS) tests. The results provide the empirical basis of individual treatment and programmatic effectiveness, and public health policy. Patients consent to witnessed testing but most tests are unwitnessed. The purpose of the present study was to compare treatment effectiveness estimates derived from witnessed versus unwitnessed urine samples. Methods We adopted a policy requiring visually witnessed urine drug screens (WUDS) and studied its impact (a single group, pretest-posttest design) on the RUDS test results in 115 male veterans enrolled in the St. Louis VA Opioid Treatment Program. Results The percentage of opioid-positive urine samples increased significantly following implementation of WUDS (25% vs. 41%, χ2 = 66.5, p <.001). Conclusions and Scientific Significance Results of this preliminary study suggest that random testing alone does not ensure the integrity of UDS testing. Outcome calculations based on random unwitnessed tests may overestimate the effectiveness of opioid dependence disorder treatment. (Am J Addict 2013;22:175-177)

Original languageEnglish
Pages (from-to)175-177
Number of pages3
JournalAmerican Journal on Addictions
Issue number2
StatePublished - Mar 2013


Dive into the research topics of 'Witnessed versus Unwitnessed Random Urine Tests in the Treatment of Opioid Dependence'. Together they form a unique fingerprint.

Cite this